Lanreotide Somatuline Application Scope

Lanreotide (Somatuline) is a long-acting somatostatin analog used in the treatment of neuroendocrine tumors (NETs), particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and acromegaly. Lanreotide is also used to treat carcinoid syndrome symptoms, helping to control the overproduction of hormones such as serotonin.

For patients with acromegaly, it helps in reducing growth hormone (GH) levels, while in neuroendocrine tumors, it reduces tumor growth and associated hormone secretion. Lanreotide is typically administered to patients who have not responded well to other treatments, offering an alternative with a longer duration of action.

Lanreotide Somatuline Characteristics

Ingredients:
- Active ingredient: Lanreotide (as lanreotide acetate)
- Excipients: Includes mannitol, water for injection, and other stabilizers.
Properties:Lanreotide is a somatostatin analog that works by mimicking the natural hormone somatostatin, which inhibits the release of several hormones including growth hormone, insulin, and glucagon. It helps control the secretion of hormones that contribute to the symptoms of acromegaly and neuroendocrine tumors, thus reducing tumor size and improving related symptoms.
Specification:
- Somatuline Autogel® is available as an injectable formulation:
  - 60 mg/0.5 mL
  - 90 mg/0.5 mL
  - 120 mg/0.5 mL
- Administered subcutaneously.

Packaging Specification:

Ingredients:Each vial contains lanreotide acetate as the active ingredient.
Properties:Lanreotide is a clear solution for subcutaneous injection.
Specification:Available in pre-filled syringes and single-use vials.
Storage:
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
- Do not freeze.
Effective period:Shelf life of 36 months from the manufacturing date.
Approval Number:Specific approval numbers based on regulatory bodies (e.g., FDA, EMA, etc.).
Manufacturer:Ipsen Biopharmaceuticals, Inc.

Guidelines For The Use Of Lanreotide Somatuline

Dosage and Administration:
- The recommended dose for neuroendocrine tumors is 120 mg every 4 weeks.
- For acromegaly, Lanreotide is typically administered as 90 mg every 4 weeks, with the possibility of increasing the dose depending on patient response.
- The subcutaneous injection is typically given in the upper arm, thigh, or abdomen.
Adverse Reactions:
- Common side effects include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain.
- Other side effects may include headache, fatigue, pain at the injection site, and bradycardia (slow heart rate).
- Serious side effects may include gallbladder disease and pancreatitis.

Medication Limitations

Contraindications:
- Hypersensitivity to lanreotide or any of its excipients.
- Not recommended for patients with severe liver impairment or gallbladder disease.
Precautions:
- Monitor liver function, gallbladder function, and blood sugar levels during treatment.
- Caution should be exercised in patients with a history of cardiac arrhythmias or those on medication that affects heart rate.

Lanreotide Somatuline Interactions

Drug Interactions:
- Insulin and other antidiabetic drugs: Lanreotide can reduce insulin secretion, so adjustments to diabetes treatment may be required.
- Cyclosporine: Lanreotide may increase cyclosporine levels in the blood, requiring dose adjustment.
- Other somatostatin analogs and dopamine agonists: Use with caution, as they may have additive effects.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Drug Import and Export Wholesaler. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.